Gilead Sciences' new HIV prevention drug has been added to CVS Health's commercial insurance plans, the drugmaker's CEO Daniel O'Day said at a major industry conference that kicked off on Monday in Sa... ...

CVS Health Corporation (NYSE:CVS) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer made bullish comments on the stock during the episode, as he remarked: “The sixth best sector and the only other sector to finish 2025 up double digits was healthcare, which finished up 12.5%. Coming into last year, there was a lot of worry about what the health and human services department might do to the industry under the leadership of RFK Jr. But when the worst of these fears fail ...

CVS Health Corporation (NYSE:CVS) is one of the most undervalued blue chip stocks to buy now. Bernstein Raises PT on CVS Health (CVS) to $91, Reiterates ‘Market Perform’ Rating On January 6, 2026, Bernstein increased its price target on CVS Health Corporation (NYSE:CVS) from $87 to $91, while reiterating a ‘Market Perform’ rating. The investment firm expects a broader inflection in the government-managed care organization (MCO) sector beginning in 2026. The firm projects short-term earnings recovery, dri ...

We recently published 9 Stocks Jim Cramer Talked About.  CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer talked about. CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical chains in America. Its shares are up by 73% over the past year. JPMorgan named the firm as a Top Pick in December, as it pointed out that CVS Health Corporation (NYSE:CVS)’s investor day had left it impressed about the firm’s earnings growth throughout 2028. The bank also raised the share price target ...

（文章来源：每日经济新闻） 每经AI快讯，1月9日，美股盘后，健康保险公司股价小幅上涨，联合健康股价上涨0.8%，CVS健康集 团股价上涨0.4%，Humana股价上涨0.9%，Centene股价上涨0.9%。 ...

Key Points Building on a strong 2025, CVS Health's outlook for 2026 and beyond looks promising. Amgen is developing newer drug products that will address a recent patent cliff. Both stocks are strong options for dividend seekers to add to their portfolios. 10 stocks we like better than CVS Health › Last year was a rebound one for CVS Health (NYSE: CVS) and Amgen (NASDAQ: AMGN). After underperforming broader equities in 2024, both healthcare giants bounced back in 2025, outperforming the market ha ...

瑞银的一份研究报告显示，DRAM供应短缺预计将持续至2027年第一季度，其中DDR4以及DDR5内存 条的需求程度料在这期间远远超供应增速。瑞银预计，在2025年第四季度，DDR系列热门产品的合约 定价可能环比大幅上涨35%，NAND闪存价格预计上涨20%，涨幅均超出此前预期;瑞银预计2026年第一 季度，DDR系列热门产品的合约定价料将进一步上涨40%，NAND价格料上涨20%。 （原标题：?新一轮流感来袭! 美国多地流感用药告急 奥司他韦紧缺程度堪比DDR内存条） 智通财经APP获悉，根据美国卫生系统药剂师协会(简称ASHP)周三发布的一项重磅统计数据，随着美 国因流感样症状就诊的医院门诊量达到二十多年来的最高水平，流感特效药物达菲(Tamiflu，也被称作 磷酸奥司他韦)目前在美国多个地区处于极度短缺状态。 不止美国，在全球范围，尤其是面临寒冬的地区，奥司他韦短缺程度甚至胜过DDR系列内存条。在北 美与欧洲的部分寒冷地区，患者端的紧迫性、药房端的补货难度和体感焦虑，甚至比买DDR系列 DRAM内存条产品还夸张。相比之下，奥司他韦式全球冬季流感时期的季节性严重短缺，而DDR内存 条则是"结构性供需错配"式 ...

ASHP在一份披露报告中指出，由于这种抗病毒药物突然间出现短缺，负责监测药品供应的ASHP目前 正在紧急评估短缺程度，并补充称历年来流感活动非常频繁的寒冷地区正面临最为严重的供应稀缺。 ASHP药学实践与质量高级总监Michael Ganio在一份声明中表示，由于目前正在全球范围流行的一种比 往年流感更加严重的流感毒株，短缺扩散"只是时间问题"。 不过，总部位于美国的连锁药房运营龙头CVS Health(CVS.US)表示，尽管其门店对磷酸奥司他韦的需求 持续激增，但并不存在全美范围的广泛短缺，某些常年流感严重的地区短缺比其他地区严重得多。其多 年来最强劲的竞争对手Walgreens去年被纽约私募股权公司Sycamore Partners全面私有化，该药房运营商 则表示，其药房的全美网络总体上"需求很高，库存极度紧张"。 智通财经APP获悉，根据美国卫生系统药剂师协会(简称ASHP)周三发布的一项重磅统计数据，随着美 国因流感样症状就诊的医院门诊量达到二十多年来的最高水平，流感特效药物达菲(Tamiflu，也被称作 磷酸奥司他韦)目前在美国多个地区处于极度短缺状态。 不止美国，在全球范围，尤其是面临寒冬的地区 ...

根据美国卫生系统药剂师协会(简称ASHP)周三发布的一项重磅统计数据，随着美国因流感样症状就诊 的医院门诊量达到二十多年来的最高水平，流感特效药物达菲(Tamiflu，也被称作磷酸奥司他韦)目前在 美国多个地区处于极度短缺状态。 CNN援引美国疾控中心(U.S.CDC)数据独家报道称，此次流感治疗药物奥司他韦短缺发生之际，由常见 流感症状(发烧加咳嗽或喉咙痛)导致的全美医院就诊量已达到至少自1997-98流感季以来的最高水平。 由于迄今只有43%的美国人接种了该类抗病毒疫苗，今年创纪录的流感季被归因于常见流感毒株H3N2 的一次重大意义基因突变，该突变导致出现一种新型的快速传播突变体，被称为K亚分支(subclade K)。 在2025年的最后一周，8.2%的医院就诊规模是因流感样症状，而一年前则为6.7%;在2025-2026流感季期 间，出现了9例与流感症状相关的儿童死亡病例，美国疾控中心本周早些时候表示。 不止美国，在全球范围，尤其是面临寒冬的地区，奥司他韦短缺程度甚至胜过DDR系列内存条。在北 美与欧洲的部分寒冷地区，患者端的紧迫性、药房端的补货难度和体感焦虑，甚至比买DDR系列 DRAM内存条产品还 ...

A new report from Hunterbrook Media investigates how the three biggest health care giants in the U.S.— CVS Health Corp. (NASDAQ:CVS) , UnitedHealth Group, Inc. (NYSE:UNH) and Cigna Group (NYSE:CI) — are allegedly using shell companies to hide billions of dollars that Hunterbrook says should be used to lower drug prices for patients.UNH stock is moving. See the chart and price action here. Benzinga reached out to CVS, Cigna and UnitedHealth for comment. CVS declined to comment, while Cigna and UnitedHealth d ...